Risk of adverse events associated with deferasirox in patients using iron chelators
碩士 === 國立陽明大學 === 衛生福利研究所 === 100 === Background Iron chelators (deferasirox or desferrioxamine) are essential to patients who need life-long blood transfusion (e.g. β-Thalassemia). However, in 2009 and 2010, the US Food and Drug Administration (FDA) had issued a warning on potential adverse events...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2012
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/76298466089553341765 |